Press Releases2017-09-13T20:17:34+00:00

Press Releases

Uptake of Biogen’s Tecfidera and Increased Availability of Merck KGaA’s Mavenclad Fueling Significant Increase in Oral Disease-Modifying Therapy Share of Multiple Sclerosis Patients in Europe to the Detriment of Teva’s Copaxone

Lack of access to Roche's Ocrevus for primary progressive multiple sclerosis has stymied UK prescriber base growth and adoption over the past six months as much of Ocrevus' early adoption in other EU countries came from first-line use among primary progressive multiple sclerosis patients due to the high unmet need and the agent's first-to-market indication

October 9, 2018|

More Rheumatologists are Using Pfizer’s Xeljanz in Psoriatic Arthritis Patients, Outpacing the Impressive Growth Displayed by Eli Lilly’s Taltz in the Previous Quarter

The most recent quarterly results of a study conducted by Spherix Global Insights with 100 US rheumatologists reveals that Xeljanz's user base has increased by a greater margin than the user base for Taltz for the treatment of psoriatic arthritis (PsA) over the last three months.

October 8, 2018|

Analysis of Over 1,000 Atopic Dermatitis Patients Highlights Moderate-to-Severe Patient Candidacy for Biologics and Small Molecules and Real-World Treatment Patterns for Patients Treated With Sanofi/Regeneron’s Dupixent

Candidacy analysis for pipeline agents reveals that JAK inhibitors, such as Pfizer's PF-0496582, AbbVie's upadacitinib and Incyte's topical ruxolitinib have the most potential upside if approved Download Report Overview EXTON, Pa., September 27, 2018 (Newswire.com) - To better understand what real-world moderate and severe atopic dermatitis patients look like in terms of disease burden, physician touchpoints, comorbidities and treatment journeys, Spherix Global Insights collaborated with 132 U.S. dermatologists and 65 allergists to analyze the records of 1,002 atopic dermatitis patients currently prescribed at least one pharmacologic agent for their disease. While the audit captured a host of clinical and non-clinical [...]

September 27, 2018|

Genentech’s Ocrevus Positioning as an Appropriate First-Line Option in Relapsing Remitting Multiple Sclerosis Appears to Be Resonating With a Subset of U.S. Neurologists

Unaided awareness of EMD Serono's Mavenclad (cladribine tablets) and Novartis' siponimod increased compared to previous quarters, but neurologists appear split on how, or if, they will incorporate the newest agents into their multiple sclerosis armamentarium, according to a new report from Spherix Global Insights Download Report Overview EXTON, PA, September 19, 2018 (Newswire.com) - A recent survey of U.S. neurologists (n=99) finds that the multiple sclerosis (MS) market remains focused on Genentech’s Ocrevus 18 months postlaunch with strong uptake displacing Biogen’s Tysabri as the monoclonal antibody (mAb) class leader for the first time. In the current quarter of the ongoing [...]

September 19, 2018|

Latest Biologic Launch in Psoriasis, UCB’s Cimzia, Having a Tough Time Getting Traction, But Developing a Presence in Dermatology May Lay Foundation for Bimekizumab in the Future

Janssen's Tremfya continues to post gains, but may soon face competition as Sun Dermatology readies for the launch of Ilumya (tildrakizumab), the second IL-23 inhibitor to be introduced in the U.S. market, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., September 14, 2018 (Newswire.com) - In the latest quarterly survey of 102 U.S. dermatologists conducted in August 2018, the launch of Cimzia (certolizumab pegol) is benchmarked against other recent launches in psoriasis including Eli Lilly’s Taltz (ixekizumab), Ortho Dermatologics’ Siliq (brodalumab) and Tremfya (guselkumab). Early assessment of Cimzia three months post-launch suggests the brand [...]

September 14, 2018|

Ankylosing Spondylitis Market Largely Dominated by TNF-Inhibitors, Though Novartis’ Cosentyx Enjoyed Significant Year Over Year Gains and a Growing Percent of Rheumatologists Report Off-Label Use of Pfizer’s Xeljanz

With no current FDA approved biologics for the treatment of non-radiographic axial spondyloarthropathy, overall penetration of biologics/JAKs is significantly lower than for ankylosing spondylitis; however, when these agents are prescribed, brand usage closely mirrors the ankylosing spondylitis indication, according to a new publication by Spherix Global Insights Download Report Overview EXTON, Pa., September 6, 2018 (Newswire.com) - Spherix Global Insights has just released the results of an independent report based on a survey of 104 US rheumatologists which highlights differences in the management of patients with active ankylosing spondylitis (AS) and those with non-radiographic axial spondyloarthropathy (nr-axSpA). The report is [...]

September 6, 2018|